SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2179078

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2179078

AI-Driven Precision Oncology Platforms Market Forecasts to 2034 - Global Analysis By Platform Component (Software and Services), AI Technology, Data Modality, Clinical Application, End User and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global AI-Driven Precision Oncology Platforms Market is estimated at $3.2 billion in 2026 and is expected to reach $13.4 billion by 2034, growing at a CAGR of 19.6% during the forecast period. AI-Driven Precision Oncology Platforms utilize machine learning, deep learning, natural language processing, and multimodal analytics to interpret molecular, clinical, and imaging data for personalized cancer management. Increasing cancer prevalence, growing adoption of genomic profiling, and demand for individualized treatment decisions are driving market growth. Technological advancements in generative AI, molecular diagnostics, and predictive analytics are improving clinical decision support. Expanding investment in precision medicine, oncology research, and digital healthcare infrastructure creates opportunities across hospitals, cancer centers, and pharmaceutical companies.

Market Dynamics:

Driver:

Increasing demand for personalized cancer treatment and AI-enabled clinical decision support

Increasing demand for personalized cancer treatment and AI-enabled clinical decision support is driving adoption of precision oncology platforms. Healthcare providers increasingly utilize genomic profiling, molecular diagnostics, and artificial intelligence to identify actionable biomarkers and support treatment selection. These platforms help clinicians interpret complex molecular information and evaluate targeted therapy options. Growing cancer prevalence, expanding precision medicine programs, and increasing availability of genomic data encourage adoption. Advances in machine learning and clinical data integration further strengthen market development.

Restraint:

High implementation costs and challenges in clinical data integration

High implementation costs and challenges in clinical data integration restrain adoption of AI-driven precision oncology platforms. Advanced solutions require sophisticated computational infrastructure, secure data environments, specialized personnel, and integration with existing hospital information systems. Differences in genomic data formats, electronic health records, and diagnostic workflows complicate interoperability. Limited reimbursement for certain AI-enabled services and uncertainty regarding clinical validation create additional barriers. Smaller healthcare organizations may face financial and technical challenges when implementing comprehensive platforms.

Opportunity:

Expansion of multimodal AI and integrated precision oncology applications

Expansion of multimodal AI and integrated precision oncology applications presents significant growth opportunities. Advanced platforms combine genomic profiles, digital pathology, medical imaging, and clinical records to generate comprehensive patient insights. Generative AI and foundation models offer opportunities to improve molecular interpretation, clinical trial matching, and treatment research. Pharmaceutical companies increasingly utilize AI-driven analytics for biomarker discovery and targeted therapy development. Growing investment in integrated healthcare data platforms and personalized oncology supports technological innovation.

Threat:

Algorithm reliability concerns and increasing patient data security risks

Algorithm reliability concerns and increasing patient data security risks pose significant challenges to AI-driven precision oncology platforms. Inaccurate molecular interpretations, biased training datasets, or poorly validated predictions may influence clinical decisions. Processing sensitive genomic and patient information creates cybersecurity and confidentiality concerns. Increasing regulatory scrutiny and requirements for explainable artificial intelligence raise development costs. Competition from established clinical decision support systems and conventional molecular interpretation workflows further challenges commercialization and widespread adoption.

Covid-19 Impact:

The COVID-19 pandemic accelerated healthcare digitalization and increased interest in remote clinical collaboration and AI-enabled diagnostic technologies. Oncology organizations explored digital platforms to support molecular tumor boards, clinical data interpretation, and treatment planning during disruptions to routine services. However, delayed cancer diagnoses, interrupted clinical trials, and constrained healthcare budgets affected implementation activities. Subsequent investment in digital healthcare infrastructure, precision medicine, and AI-supported oncology workflows continues to encourage market development.

The software segment is expected to be the largest during the forecast period

The software segment is expected to account for the largest market share during the forecast period due to increasing adoption of AI-enabled molecular interpretation, clinical decision support, and integrated oncology analytics platforms. Software solutions combine genomic data, electronic health records, and diagnostic information to support personalized treatment decisions. Growing investment in precision oncology programs, cloud-based healthcare platforms, and automated biomarker analysis encourages adoption. Advances in machine learning, workflow integration, and scalable clinical analytics strengthen segment growth.

The multimodal AI & foundation models segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the multimodal AI & foundation models segment is predicted to witness the highest growth rate due to increasing demand for integrated interpretation of diverse oncology datasets. These technologies combine genomic information, pathology images, radiology findings, and clinical records to support comprehensive cancer assessment. Advances in foundation models, generative AI, and computational infrastructure improve analytical capabilities. Growing investment in personalized treatment prediction, biomarker discovery, and oncology research is expected to accelerate adoption.

Region with largest share:

During the forecast period, North America is expected to hold the largest share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and extensive precision oncology activities. The United States leads regional development through biotechnology companies, cancer research centers, and healthcare organizations deploying AI-enabled molecular interpretation platforms. Increasing adoption of genomic testing, established clinical trial networks, and growing demand for personalized treatment encourage utilization. Technological innovation and partnerships between diagnostic developers and healthcare providers strengthen commercialization.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing cancer prevalence, and growing investment in artificial intelligence technologies. China, Japan, India, South Korea, and Australia are advancing precision oncology programs and genomic testing capabilities. Improving access to molecular diagnostics, expanding digital healthcare initiatives, and increasing clinical research encourage adoption. Government technology investments and collaborations between healthcare institutions and biotechnology companies support regional growth.

Key players in the market

Some of the key players in the AI-Driven Precision Oncology Platforms Market include Tempus AI, Inc., Caris Life Sciences, Inc., SOPHiA GENETICS SA, Foundation Medicine, Inc., Guardant Health, Inc., BostonGene Corporation, GenomOncology LLC, Perthera, Inc., Owkin, Inc., PathAI, Inc., Artera, Inc., QIAGEN N.V., Fabric Genomics, Inc., Flatiron Health, Inc., Syapse, Inc., Roche Holding AG, Illumina, Inc., and Microsoft Corporation.

Key Developments:

In October 2026, Tempus AI, Inc. announced an expanded multi-year strategic collaboration with Bristol Myers Squibb to provide multimodal oncology data and access to its AI-powered Lens platform. The agreement supports oncology drug discovery, clinical research, and the development of advanced AI models for identifying therapeutic targets and improving precision oncology research.

In August 2026, Caris Life Sciences, Inc. announced the publication of research in npj Precision Oncology demonstrating an AI-driven approach to predicting first-line treatment benefit in pancreatic cancer. The study evaluated Caris AI Insights molecular signatures to support personalized therapy selection and improve clinical decision-making.

In June 2026, SOPHiA GENETICS SA announced a memorandum of understanding with Memorial Sloan Kettering Cancer Center to explore establishing a precision medicine joint venture. The collaboration aims to combine clinical diagnostic expertise with the SOPHiA DDM AI platform to develop and deploy advanced precision oncology solutions.

Platform Components Covered:

  • Software
  • Services

AI Technologies Covered:

  • Machine Learning & Predictive Analytics
  • Deep Learning & Neural Networks
  • Natural Language Processing
  • Generative AI & Large Language Models
  • Multimodal AI & Foundation Models
  • Knowledge Graph-Based AI
  • Explainable & Interpretable AI
  • Other AI Technologies

Data Modalities Covered:

  • Genomic & Molecular Profiling Data
  • Transcriptomic & Proteomic Data
  • Digital Pathology Data
  • Radiology & Medical Imaging Data
  • Electronic Health Records & Clinical Data
  • Liquid Biopsy & Circulating Biomarker Data
  • Integrated Multi-Omics & Multimodal Data
  • Other Data Modalities

Clinical Applications Covered:

  • Molecular Biomarker Identification & Interpretation
  • Personalized Treatment Selection
  • Targeted Therapy & Immunotherapy Response Prediction
  • Cancer Prognosis & Risk Stratification
  • Treatment Resistance & Disease Progression Prediction
  • Molecular Tumor Board Decision Support
  • Clinical Trial Matching & Patient Stratification
  • Precision Oncology Drug Discovery & Development
  • Other Clinical Applications

End Users Covered:

  • Hospitals & Health Systems
  • Cancer Centers & Oncology Clinics
  • Molecular Diagnostic & Genomics Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic Medical Centers & Research Institutions
  • Diagnostic & Reference Laboratories
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC40927

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Driven Precision Oncology Platforms Market, By Platform Component

  • 5.1 Software
    • 5.1.1 Standalone Precision Oncology Software
    • 5.1.2 Integrated Precision Oncology Platforms
  • 5.2 Services
    • 5.2.1 Implementation & Integration Services
    • 5.2.2 Clinical Interpretation & Consulting Services
    • 5.2.3 Support & Maintenance Services

6 Global AI-Driven Precision Oncology Platforms Market, By AI Technology

  • 6.1 Machine Learning & Predictive Analytics
  • 6.2 Deep Learning & Neural Networks
  • 6.3 Natural Language Processing
  • 6.4 Generative AI & Large Language Models
  • 6.5 Multimodal AI & Foundation Models
  • 6.6 Knowledge Graph-Based AI
  • 6.7 Explainable & Interpretable AI
  • 6.8 Other AI Technologies

7 Global AI-Driven Precision Oncology Platforms Market, By Data Modality

  • 7.1 Genomic & Molecular Profiling Data
  • 7.2 Transcriptomic & Proteomic Data
  • 7.3 Digital Pathology Data
  • 7.4 Radiology & Medical Imaging Data
  • 7.5 Electronic Health Records & Clinical Data
  • 7.6 Liquid Biopsy & Circulating Biomarker Data
  • 7.7 Integrated Multi-Omics & Multimodal Data
  • 7.8 Other Data Modalities

8 Global AI-Driven Precision Oncology Platforms Market, By Clinical Application

  • 8.1 Molecular Biomarker Identification & Interpretation
  • 8.2 Personalized Treatment Selection
  • 8.3 Targeted Therapy & Immunotherapy Response Prediction
  • 8.4 Cancer Prognosis & Risk Stratification
  • 8.5 Treatment Resistance & Disease Progression Prediction
  • 8.6 Molecular Tumor Board Decision Support
  • 8.7 Clinical Trial Matching & Patient Stratification
  • 8.8 Precision Oncology Drug Discovery & Development
  • 8.9 Other Clinical Applications

9 Global AI-Driven Precision Oncology Platforms Market, By End User

  • 9.1 Hospitals & Health Systems
  • 9.2 Cancer Centers & Oncology Clinics
  • 9.3 Molecular Diagnostic & Genomics Laboratories
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Contract Research Organizations
  • 9.6 Academic Medical Centers & Research Institutions
  • 9.7 Diagnostic & Reference Laboratories
  • 9.8 Other End Users

10 Global AI-Driven Precision Oncology Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Tempus AI, Inc.
  • 13.2 Caris Life Sciences, Inc.
  • 13.3 SOPHiA GENETICS SA
  • 13.4 Foundation Medicine, Inc.
  • 13.5 Guardant Health, Inc.
  • 13.6 BostonGene Corporation
  • 13.7 GenomOncology LLC
  • 13.8 Perthera, Inc.
  • 13.9 Owkin, Inc.
  • 13.10 PathAI, Inc.
  • 13.11 Artera, Inc.
  • 13.12 QIAGEN N.V.
  • 13.13 Fabric Genomics, Inc.
  • 13.14 Flatiron Health, Inc.
  • 13.15 Syapse, Inc.
  • 13.16 Roche Holding AG
  • 13.17 Illumina, Inc.
  • 13.18 Microsoft Corporation
Product Code: SMRC40927

List of Tables

  • Table 1 Global AI-Driven Precision Oncology Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI-Driven Precision Oncology Platforms Market Outlook, By Platform Component (2023-2034) ($MN)
  • Table 3 Global AI-Driven Precision Oncology Platforms Market Outlook, By Software (2023-2034) ($MN)
  • Table 4 Global AI-Driven Precision Oncology Platforms Market Outlook, By Standalone Precision Oncology Software (2023-2034) ($MN)
  • Table 5 Global AI-Driven Precision Oncology Platforms Market Outlook, By Integrated Precision Oncology Platforms (2023-2034) ($MN)
  • Table 6 Global AI-Driven Precision Oncology Platforms Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global AI-Driven Precision Oncology Platforms Market Outlook, By Implementation & Integration Services (2023-2034) ($MN)
  • Table 8 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Interpretation & Consulting Services (2023-2034) ($MN)
  • Table 9 Global AI-Driven Precision Oncology Platforms Market Outlook, By Support & Maintenance Services (2023-2034) ($MN)
  • Table 10 Global AI-Driven Precision Oncology Platforms Market Outlook, By AI Technology (2023-2034) ($MN)
  • Table 11 Global AI-Driven Precision Oncology Platforms Market Outlook, By Machine Learning & Predictive Analytics (2023-2034) ($MN)
  • Table 12 Global AI-Driven Precision Oncology Platforms Market Outlook, By Deep Learning & Neural Networks (2023-2034) ($MN)
  • Table 13 Global AI-Driven Precision Oncology Platforms Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 14 Global AI-Driven Precision Oncology Platforms Market Outlook, By Generative AI & Large Language Models (2023-2034) ($MN)
  • Table 15 Global AI-Driven Precision Oncology Platforms Market Outlook, By Multimodal AI & Foundation Models (2023-2034) ($MN)
  • Table 16 Global AI-Driven Precision Oncology Platforms Market Outlook, By Knowledge Graph-Based AI (2023-2034) ($MN)
  • Table 17 Global AI-Driven Precision Oncology Platforms Market Outlook, By Explainable & Interpretable AI (2023-2034) ($MN)
  • Table 18 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other AI Technologies (2023-2034) ($MN)
  • Table 19 Global AI-Driven Precision Oncology Platforms Market Outlook, By Data Modality (2023-2034) ($MN)
  • Table 20 Global AI-Driven Precision Oncology Platforms Market Outlook, By Genomic & Molecular Profiling Data (2023-2034) ($MN)
  • Table 21 Global AI-Driven Precision Oncology Platforms Market Outlook, By Transcriptomic & Proteomic Data (2023-2034) ($MN)
  • Table 22 Global AI-Driven Precision Oncology Platforms Market Outlook, By Digital Pathology Data (2023-2034) ($MN)
  • Table 23 Global AI-Driven Precision Oncology Platforms Market Outlook, By Radiology & Medical Imaging Data (2023-2034) ($MN)
  • Table 24 Global AI-Driven Precision Oncology Platforms Market Outlook, By Electronic Health Records & Clinical Data (2023-2034) ($MN)
  • Table 25 Global AI-Driven Precision Oncology Platforms Market Outlook, By Liquid Biopsy & Circulating Biomarker Data (2023-2034) ($MN)
  • Table 26 Global AI-Driven Precision Oncology Platforms Market Outlook, By Integrated Multi-Omics & Multimodal Data (2023-2034) ($MN)
  • Table 27 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other Data Modalities (2023-2034) ($MN)
  • Table 28 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Application (2023-2034) ($MN)
  • Table 29 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Biomarker Identification & Interpretation (2023-2034) ($MN)
  • Table 30 Global AI-Driven Precision Oncology Platforms Market Outlook, By Personalized Treatment Selection (2023-2034) ($MN)
  • Table 31 Global AI-Driven Precision Oncology Platforms Market Outlook, By Targeted Therapy & Immunotherapy Response Prediction (2023-2034) ($MN)
  • Table 32 Global AI-Driven Precision Oncology Platforms Market Outlook, By Cancer Prognosis & Risk Stratification (2023-2034) ($MN)
  • Table 33 Global AI-Driven Precision Oncology Platforms Market Outlook, By Treatment Resistance & Disease Progression Prediction (2023-2034) ($MN)
  • Table 34 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Tumor Board Decision Support (2023-2034) ($MN)
  • Table 35 Global AI-Driven Precision Oncology Platforms Market Outlook, By Clinical Trial Matching & Patient Stratification (2023-2034) ($MN)
  • Table 36 Global AI-Driven Precision Oncology Platforms Market Outlook, By Precision Oncology Drug Discovery & Development (2023-2034) ($MN)
  • Table 37 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other Clinical Applications (2023-2034) ($MN)
  • Table 38 Global AI-Driven Precision Oncology Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 39 Global AI-Driven Precision Oncology Platforms Market Outlook, By Hospitals & Health Systems (2023-2034) ($MN)
  • Table 40 Global AI-Driven Precision Oncology Platforms Market Outlook, By Cancer Centers & Oncology Clinics (2023-2034) ($MN)
  • Table 41 Global AI-Driven Precision Oncology Platforms Market Outlook, By Molecular Diagnostic & Genomics Laboratories (2023-2034) ($MN)
  • Table 42 Global AI-Driven Precision Oncology Platforms Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 43 Global AI-Driven Precision Oncology Platforms Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 44 Global AI-Driven Precision Oncology Platforms Market Outlook, By Academic Medical Centers & Research Institutions (2023-2034) ($MN)
  • Table 45 Global AI-Driven Precision Oncology Platforms Market Outlook, By Diagnostic & Reference Laboratories (2023-2034) ($MN)
  • Table 46 Global AI-Driven Precision Oncology Platforms Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!